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Intravitreal Bevacizumab Alone versus Combined with 
Macular Photocoagulation in Diabetic Macular Edema
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Department of Ophthalmology, Inha University School of Medicine, Incheon, Korea
Purpose: To compare the efficacy between intravitreal bevacizumab and combination treatment (bevacizumab and 
macular photocoagulation) for the treatment of diabetic macular edema (DME). In addtion, changes of DME type 
were researched using optical coherence tomography.
Methods: The present study included 90 eyes with bevacizumab injection and 38 eyes with combination treatment. 
Using chart records, patients were reviewed until 6 months after treatment. The present study compared changes 
of visual acuity (VA) and macular thickness at each follow up. DME was classified into 4 types and the morpho-
logic pattern was compared.
Results: In patients with the bevacizumab injection only, VA improved from 0.29 ± 0.18 to 0.48 ± 0.26 at 1 month and 
returned to 0.32 ± 0.20 at 6 months after treatment. In the combination treatment, VA improved from 0.32 ± 0.22 
to 0.52 ± 0.26 at 1 month and returned to 0.36 ± 0.18 at 6 months after treatment. There was no significant im-
provement of VA at the final follow‐up with either treatment. There was significant decrease of macular thickness 
except in the mixed DME type.
Conclusions: The combination treatment did not yield better VA or macular thickness reduction at 6 months than 
bevacizumab injection alone. By classifying and observing the change of DME type, determining the treatment 
objectively and predicting the effectiveness of treatment can be helpful.
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Diabetic retinopathy is the leading cause of blindness in 
people of working age. Diabetic macular edema (DME) af-
fects approximately 29% of diabetic patients with disease du-
ration of 20 years or more and is the main reason for reduced 
vision in this segment of population [1]. The Early Treatment 
Diabetic Retinopathy Study (ETDRS) showed the 3- year 
risk of moderate visual loss for diabetic patients with clin-
ically significant macular edema was 30% [2]. In the ETDRS 
study, laser photocoagulation reduced the risk of moderate 
visual acuity loss for all eyes with DME and mild to moder-
ate non-proliferative diabetic retinopathy by approximately 
50% [3-5]. However, 12% of the treated eyes still lost 15 or 
more ETDRS letters at the 3-year follow-up interval [6,7]. 
Furthermore, less than 3% of treated eyes demonstrated an 
improvement in visual acuity of the same magnitude [4]. 
Over time, laser burns may develop into areas of progressive 
retinal pigment epithelium and retinal atrophy that become 
larger than the original laser spot size and encroach on 
fixation. Photocoagulation for DME may be associated with 
central scotomas associated with loss of central vision and 
decreased color vision [8,9]. 
In attempt to reduce these limitations, intravitreal triamcinolone 
acetonide (TA) or anti-vascular endothelial growth factor 
(VEGF) agent was injected in patients with DME and favorable 
results were shown in previous studies [10-13]. However, in-
travitreal TA or anti-VEGF agent showed temporary effects 
and repeated treatments were needed [14-16]. Many retina 
specialists have studied brisk treatment modalities to cure 
DME with significant results discovered [16]. However, lim-
itations still exist such as refractory, recurrent DME, ideal 
regimen, appropriate numbers of injections and the time of 
injection interval. 
To overcome the limitation of DME treatment, various 
therapeutic options were studied. Lam et al. [17] reported 
comparable results of intravirtreal TA plus sequential grid la-Korean J Ophthalmol Vol.25, No.5, 2011
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Fig. 1. The classification of diabetic macular edema according to optical coherence tomography features. (A) Diffuse macular edema: 
thickening of the fovea with homogeneous optical reflectivity throughout the whole layer of the retina. (B) Cystoid macular edema: thick-
ening of the fovea forming cystic space with markedly decreased optical reflectivity in the outer retinal layer. (C) Serous retinal detach-
ment: foveal detachment without vitreomacular traction. (D) Mixed macular edema: combination of the above 3 types of macular edema 
occupying approximately the same proportion, respectively.
ser versus TA or laser alone. Their results showed combina-
tion treatment did not yield a better effect for treating DME. 
Kim et al. [18] reported another result regarding a different 
effect of intravitreal TA according to the DME morphologic 
type. To the authors’ knowledge, to date there are no re-
ported results regarding the combination treatment of intra-
vitreal bevacizumab plus macular laser or different effects 
of intravitreal bevacizumab injection according to DME 
pattern and change of DME pattern after the bevacizumab 
injection. 
Therefore, the authors of the present study investigated the 
efficacy of intravitreal bevacizumab injection alone or in 
combination with macular photocoagulation and the change 
of DME pattern with optical coherence tomography (OCT) 
findings after each treatment. 
Materials and Methods
This retrospective study was approved by the Review 
Board/Ethics Committee of our hospital.
Participants
The present study included 128 eyes of 120 patients from 
May 2008 to May 2009. Patients were treated with intra-
vitreal bevacizumab injection or intravitreal bevacizumab in-
jection plus macular laser for DME. The macular edema was 
diagnosed on slit lamp biomicroscopy and confirmed with ei-
ther fluorescein angiography (FAG) or OCT. Exclusion cri-
teria included macular edema secondary to causes other than 
diabetic retinopathy, signs of vitreomacular traction, aphakia 
and history of glaucoma or ocular hypertension. Patients who 
had panretinal photocoagulation within 6 months, macular 
laser or intravitreal TA / bevacizumab injection within 12 
months, or significant media opacities were also excluded. 
Patients classification and analysis
Through retrospective chart review, patients were grouped 
into the bevacizumab injection only group or bevacizumab 
plus macular laser combination group. Bevacizumab 
(Avastin; Genentech Inc., South San Francisco, CA, USA) 
was injected into the vitreous at a dose of 2.5 mg in 0.1 mL. 
In case of combination treatment, focal or grid macular laser 
was used within approximately 1 month after bevacizumab 
injection according to investigator’s decision following FAG 
findings. Every patient underwent complete ophthalmic ex-
amination including best-corrected visual acuity, slit lamp 
examination, intraocular pressure measurement and fundu-
scopic examination after pupil dilation. Reinjection was per-
formed when macular edema still remained or recurred (50 μ
m or more increased in OCT) or visual acuity was decreased 
during the follow-up period. 
 Visual acuity, intraocular pressure, slit lamp and fundu-
scopic examination results were analyzed with chart review 
at the time of pre-treatment and post-treatment after 2 weeks, 
1 month, 2 months, 3 months and 6 months. Morphologic 
pattern of DME and central macular thickness and volume 
were also analyzed comparing pre-treatment OCT and 
post-treatment OCTSJ Lee, et al. Comparison of TA and Bevacizumab for ME
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Table 1. Patients’ demographic data and baseline characteristics
Treatment groups
p-value
Avastin injection Combination therapy
Total no. of eyes 90 38 <0.05
Mean age (yr) 61.2 ± 8.8 59.8 ± 4.1 0.58
Sex (male, %) 69.3 71.2 0.71
Mean intraocular pressure (mmHg) 13.2 12.1 0.62
Table 2. Baseline proportion of different diabetic macular 
edema types
Types of ME Treatment groups
Avastin 
(%, n=65)
Combination therapy 
(%, n=31)
Diffuse ME 44.4 (29) 47.3 (15)
CME 31.1 (20) 28.9 (9)
SRD 13.3 (9) 9.7 (3)
Mixed ME 11.1 (7) 9.7 (3)
ME = macular edema; CME = cystoid macular edema; SRD = 
serous retinal detachment.
Table 3. Changes of visual acuity after each treatment 
Treatment groups
Avastin Combination therapy
Baseline 0.29 ± 0.18 0.32 ± 0.22
2 wk 0.42 ± 0.22 0.48 ± 0.27
*
1 mon 0.48 ± 0.26
* 0.52 ± 0.26
*
2 mon 0.40 ± 0.23 0.43 ± 0.23
3 mon 0.35 ± 0.19 0.37 ± 0.20
6 mon 0.32 ± 0.20 0.36 ± 0.18
*Indicates statistically significant improvement of visual acuity 
compared to baseline visual acuity (p < 0.05).
Fig. 2. Comparison of visual acuity between intravitreal avastin and 
intravitreal avastin plus macular laser photocoagulation combina-
tion therapy. The asterisk indicates a statistically significant differ-
ence within a group (
*p <0 . 0 5 ) .
Classification of DME pattern according to OCT 
Among 128 eyes, eyes were excluded with mechanical 
traction on macula or when interpretation was not possible 
and the remaining 102 eyes (79.7%) with pre- and post-injection 
OCT results were analyzed by DME pattern. The pattern of 
DME was classified according to Otani et al. [19], such as 
diffuse macular edema, cystoids macular edema and serous 
retinal detachment. Unlike other studies, mixed macular ede-
ma, a combination of the above 2 or more types of DME, was 
used in the present study (Fig. 1). 
Statistical analyses
The data were presented as the mean ± standard deviation. 
Statistical differences between pre- and post-treatment clin-
ical data were assessed using a paired t-test. Differences be-
tween bevacizumab injection and combination therapy were 
assessed using an independent t-test (SPSS ver 12.0; SPSS 
Inc., Chicago, IL, USA). A p-value of less than 0.05 was con-
sidered to be statistically significant.
Results 
The bevacizumab injection only group and bevacizumab 
plus macular laser combination group included 90 eyes from 
85 patients and 38 eyes from 35 patients, respectively. Baseline 
characteristics such as age, sex and intraocular pressure were 
not statistically significant, however, the number of subjects 
was significantly smaller (p < 0.05) in the combination treat-
ment group than in the bevacizumab injection only group 
(Table 1). In the intravitreal bevacizumab injection only gor-
up, the type of DME before treatment was 44.4% diffuse 
macular edema, 31.1% cystoid macular edema, 13.3% serous 
retinal detachment and 11.1% mixed macular edema. In the 
combination treatment group, the type of DME before treat-
ment was 47.3% diffuse macular edema, 28.9% cystoid mac-
ular edema, 9.7% serous retinal detachment and 9.7% mixed 
macular edema. There was no statistically significant differ-
ence of DME type (p = 0.49) between the 2 groups (Table 2). 
Baseline visual acuity before treatment was 0.29 ± 0.18 in the 
bevacizumab injection only group and 0.32 ± 0.22 in the 
combination treatment group and there was no significant 
differences (p = 0.68) between the 2 groups. Until the last fol-
low-up, mean number of injections was 1.7 times in the bev-
acizumab injection only group and 1.3 times in the combina-
tion treatment group (p = 0.57) and there were no adverse 
events such as endophthalmitis or significant rise of intra-
ocular pressure and cataractous change. Korean J Ophthalmol Vol.25, No.5, 2011
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Table 4. Changes of macular thickness and volume after each treatment according to the 4 different ME types
Mean change Diffuse ME CME SRD Mixed ME
*
Pre Post Pre Post Pre Post Pre Post Pre Post
Avastin CMT (μm) 468 .1 ±105.0 374.4 ± 73.5 373.5 ± 123.0 261.0 ± 111.0 492.5 ± 162.0 362.0 ± 154.0 483.5 ± 102.0 361.0 ± 98.0 523.6 ± 162.0 532.9 ± 103.0
CMV (μm
3)   0.74 ±0.19  0.55 ± 0.11   0.60 ± 0.22   0.32 ± 0.18   0.75 ± 0.24   0.56 ± 0.11   0.72 ± 0.18   0.48 ± 0.10   0.90 ± 0.20   0.93 ± 0.12
Combination 
therapy
CMT (μm) 457.2 ± 95.2 349.0 ± 126.0 363.4 ± 95.4 241.2 ± 123.0 482.7 ± 114.0 322.6 ± 94.2 463.4 ± 145.0 331.9 ± 112.0 518.2 ± 132.0 522.8 ± 87.9
CMV (μm
3)   0.71 ± 0.19   0.49 ± 0.14   0.59 ± 0.22 0. 27 ± 0.18   0.73 ± 0.24   0.48 ± 0.11   0.70 ± 0.18   0.38 ± 0.10  0.83 ± 0.18   0.85 ± 0.11
Statistically significant decrease of macular thickness and volume after treatment except (*).
ME = diffuse macular edema; CME = cystoid macular edema; SRD = serous retinal detachment; Pre = preoperative; Post = postoperative; 
CMT = central macular thickness; CMV = central macular volume. 
Table 5. Change of macular edema type after each treatment
Change of ME type Treatment groups
Preoperative Postoperative Avastin (n, %) Combination therapy (n, %)
Diffuse ME Diffuse ME + SRD 3/29 (10.3 ) 2/15 (13.3)
Diffuse ME + CME 4/29 (13.8) 3/15 (20.0)
CME CME + diffuse ME 8/20 (40.0)   4/9 (44.4)
CME + SRD 2/20 (10.0)   1/9 (11.1)
SRD Diffuse ME   2/9 (22.2)   1/3 (33.3)
SRD + diffuse ME   2/9 (22.2)   0/3 (0)
Mixed ME Mixed ME   6/7 (85.7)   3/3 (100)
ME = macular edema; SRD = serous retinal detachment; CME = cystoid macular edema.
Change of visual acuity
Change of visual acuity after treatment was 0.42 ± 0.22 
and 0.48 ± 0.26 at 2 weeks and 1 month after intravitreal bev-
acizumab injection only, respectively. In the combination 
treatment, visual acuity after treatment was 0.48 ± 0.27 and 
0.52 ± 0.26 at 2 weeks and 1 month after treatment, respectively. 
Visual acuity was improved in both groups and when com-
paring the visual acuity at 2 weeks after treatment, change of 
visual acuity improvement was faster in the combination 
treatment group than in the bevacizumab injection only 
group. However, visual acuity slightly regressed, 0.32 ± 0.20 
in the bevacizumab injection only group and 0.36 ± 0.18 in 
the combination treatment until the last follow-up (Table 3 
and Fig. 2). 
Change of macular thickness and volume
In bevacizumab injection group, macular thickness before 
treatment was 468.1 ± 105.0 μm and decreased to 374.4 ± 
73.5 μm (p < 0.05) at 1 month after treatment. The mean 
macular volume was also decreased from 0.74 ± 0.19 μm
3 to 
0.55 ± 0.11 μm
3 (p < 0.05) at 1 month after treatment. In com-
bination treatment group, mean macular thickness was de-
creased from 457.2 ± 95.2 μm to 349.0 ± 126.0 μm (p < 0.05) 
and mean macular volume was decreased from 0.71 ± 0.19 μ
m
3 to 0.49 ± 0.14 μm
3 (p < 0.05) at 1 month after treatment. 
These show significant decrease after treatment in both 
groups (Table 4). 
Regarding the type of DME, the macular thickness and 
volume after treatment significantly decreased in patients 
with diffuse macular edema, cystoid macular edema and se-
rous retinal detachment in both groups (Table 4). However, 
in the mixed macular edema group, macular thickness and 
volume showed no improvement or even deterioration; in the 
bevacizumab injection only group, macular thickness 
changed from 523.6 ± 162.0 μm to 532.9 ± 103.0 μm and 
macular volume changed from 0.90 ± 0.20 μm
3 to 0.93 ± 0.12 
μm
3 after treatment. In the combination treatment group, 
macular thickness changed from 518.2 ± 132.0 μm to 522.8 ± 
87.9 μm and macular volume changed from 0.83 ± 0.18 μm
3 
to 0.85 ± 0.11 μm
3 (p = 0.69).
Change of diabetic macular edema type after treatment
 In the bevacizumab injection only group, 3 out of 29 eyes 
changed the type of DME after treatment from diffuse mac-
ular edema to a combination of diffuse macular edema and 
serous retinal detachment and another 4 eyes changed to a 
combination of cystoid and diffuse macular edema after 
treatment. Eight out of 20 eyes changed from cystoid mac-
ular edema to combination of diffuse and cystoid macular 
edema and another 2 eyes changed to a combination of cys-
toid macular edema and serous retinal detachment after 
treatment. Two out of 9 eyes changed from serous retinal de-
tachment to diffuse macular edema and another 2 eyes 
changed to a combination of serous retinal detachment and 
diffuse macular edema after treatment. Conversely, in mixed 
macular edema, 6 out of 7 eyes showed no change of DME 
type after treatment. 
In the combination treatment group, 2 out of 15 diffuse 
macular edemas changed to a combination of diffuse macular SJ Lee, et al. Comparison of TA and Bevacizumab for ME
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edema and serous retinal detachment and another 3 eyes 
changed to a combination of cystoid and diffuse macular ede-
ma after treatment. Four out of 9 cystoid macular edemas 
changed to cystoid and diffuse macular edema and another 1 
eye changed to cystoid macular edema and serous retinal de-
tachment after treatment. One out of 3 serous retinal detach-
ments changed to diffuse macular edema after treatment. 
Conversely, 3 out of 3 mixed macular edemas showed no 
change of DME type even after treatment (Table 5). 
Discussion
Previous studies reported results of a combination treat-
ment of intravitreal TA injection and macular laser photo-
coagulation or combination of intravitreal TA and bev-
acizumab injection as a treatment option for DME. However, 
outcomes of combination therapy showed no further benefi-
cial effects than conventional treatment [17,20,21]. Kim et 
al. [18] also evaluated the efficacy of intravitreal TA in-
jection according to DME type and concluded the cystoid 
type of macular edema responded better than other types of 
macular edema. To the authors’ knowledge, visual outcomes 
of intravitreal bevacizumab injection only and macular laser 
photocoagulation combination treatment or treatment effi-
cacies according to DME type or change of DME type after 
treatment have not yet been reported. 
The present study showed both intravitreal bevacizumab 
injection only and combination treatment achieved visual 
improvement at 1 month after treatment and visual acuity re-
gressed at 3 months after treatment. Although there were no 
significant differences between the 2 groups, visual acuity in 
the combination treatment group was better than a single 
treatment at the last follow-up. As we shown in Fig. 2, 3 months 
to 6 months showed a decrease of visual acuity in the bev-
acizumab injection only group, otherwise, the combination 
treatment group showed relatively no change of visual 
acuity. The results indicate visual acuity could be maintained 
in the combination treatment otherwise visual acuity would 
decrease with the bevacizumab injection only in a longer fol-
low-up period. The results can be explained in accordance 
with a previous study Bak et al. [22] reported; in DME, mac-
ula was diffusely thickened and fluid was accumulated in the 
outer retinal layer because of the blood-retinal barrier break-
down, therefore, the laser could not deliver sufficient power 
to the RPE layer. With a TA injection, edema could decrease 
and retinal penetration could increase, allowing the laser to 
more easily deliver power. 
The present study also assumes macular laser photocoagulation 
after decreasing macular edema with bevacizumab injection 
can reduce the recurrence of DME and maintain the visual 
acuity. However, additional studies with a longer follow-up 
period are necessary to prove this hypothesis. 
The pathogenesis of DME is not yet fully understood. The 
possible mechanism is increased vascular permeability due 
to injured capillary endothelium consisting of the blood-reti-
nal barrier [23]. The important factor is the retinal ischemic 
change produced by vascular microstructure change result-
ing from high blood sugar [23,24]. The depletion of oxygen 
causes cytotoxic edema which is the expansion of Muller 
cells and also causes vasogenic edema by secreting VEGF, 
prostaglandin and inflammatory cytokines (for example in-
terleukin-6) [25,26]. If the cellular edema and ischemia per-
sist, the outer retinal layer cyst will be made by liquefaction 
necrosis of Muller cells and other neural tissue [27,28]. 
Based upon the above pathogenesis, a theory regarding phys-
iologic change of DME deterioration upon time sequence 
was hypothesized. DME which is diffusely thickened macula 
resulting from cellular expansion caused by cytotoxic and 
vasogenic edema would be the first step. As the next step, 
sponge-like configuration of DME would be made because 
of microcellular liquefaction necrosis when edema and is-
chemia persist. If the sponge-like cysts are joined, a cystoid 
type of DME will develop while serous retinal detachment 
could be made by joining in a different manner. If the DME 
becomes worse, mixed macular edema consisting of a de-
tached macular area combining a diffuse or cystoid type of 
edema will develop. 
The present study showed macular thickness and volume 
was significantly decreased 1 month after treatment in both 
groups. However, when considering morphologic change of 
DME type, macular edema was decreased in the diffuse, cys-
toid and serous retinal detachment type but otherwise, showed 
no change or even an increase in mixed macular edema in 
both groups. According to the above hypothesis, the results 
indicate mixed macular edema, which is the last step in 
DME, could be considered refractory to DME. The reason 
could be due to the persistent deterioration of cytotoxic and 
vasogenic edema causing irreversible cellular necrosis. In 
both treatment groups, a change of macular edema type after 
treatment was found; cystoid or serous detachment portion 
decreased and changed to a diffuse type of edema after both 
treatments. The result may be due to the bevacizumab in-
jection reducing the retinal capillary vascular permeability. 
However, mixed macular edema did not respond to treatment 
because no change of macular edema type was observed even 
after treatment. The above hypothesis is can be explained by 
observation of the change in the type of macular edema; 
starting with DME and changing to cystoid or serous retinal 
detachment and returning back to DME after treatment.
The present study has several limitations such as a non- 
randomized retrospective study and including heterogeneous 
subjects. The follow-up period was relatively short to prove 
the hypothesis. The small number of patients in the combina-
tion treatment group compared to the bevacizumab injection 
only treatment group could be another limitation. 
In conclusion, there were no significant differences be-
tween the bevacizumab injection only treatment group and 
the bevacizumab injection plus macular photocoagulation 
combination treatment group through 6 months of follow-up. 
However, the present study expects a bevacizumab plus mac-Korean J Ophthalmol Vol.25, No.5, 2011
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ular photocoagulation combination treatment could maintain 
visual acuity and reduce the recurrence of macular edema. In 
both treatment groups, macular thickness and volume de-
creased after treatment except for mixed macular edema and 
macular edema which changed their type after treatment. 
According to the above results, macular edema could be hy-
pothesized to progress from diffuse edema to cystoid or se-
rous detachment and to mixed type edema. The results from 
the present study will help reduce the recurrence of macular 
edema and to decide the appropriate time of treatment by an-
alyzing the DME morphologic pattern. However, animal 
model studies regarding changes of retinal cells in DME are 
needed in the future and a prospective study with a longer 
follow up period should confirm the results.
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